Drugs Made In America Acquisition Corp. DMAA
$10.80
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.47% | -93.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.47% | -93.14% | |||
| Operating Income | 4.47% | 93.14% | |||
| Income Before Tax | -12.36% | 825.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.36% | 825.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.36% | 825.12% | |||
| EBIT | 4.47% | 93.14% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.11% | 841.94% | |||
| Normalized Basic EPS | -4.11% | 835.90% | |||
| EPS Diluted | -4.11% | 841.94% | |||
| Normalized Diluted EPS | -4.11% | 835.90% | |||
| Average Basic Shares Outstanding | -8.61% | -1.38% | |||
| Average Diluted Shares Outstanding | -8.61% | -1.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||